Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts

Neoplasia

Volumn 8, Issue 7, 2006, Pages 534-542

  Seshadri, Mukund ^a   Mazurchuk, Richard ^a   Spernyak, Joseph A ^a   Bhattacharya, Arup ^a   Rustum, Youcef M ^a   Bellnier, David A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antivascular therapies; DMXAA; Head and neck cancers; MRI; Tumor vasculature

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CD31 ANTIGEN; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER INHIBITION; CONTROLLED STUDY; DENSITY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; HEAD AND NECK CARCINOMA; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PHARYNX CARCINOMA; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SUBMANDIBULAR GLAND; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT; VASODILATATION;

EID: 33745960743     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06295     Document Type: Article

References (32)

1. Sanderson RJ and Ironside JAD (2002). Squamous cell carcinomas of the head and neck. BMJ 325, 822-827.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, and Thun MJ (2005). Cancer statistics, 2005. CA Cancer J Clin 55, 10-30.
3. Seiwert TY and Cohen EE (2005). State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92, 1341-1348.
4. Cohen EE, Lingen MW, and Vokes EE (2004). The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22, 1743-1752.
5. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, and Eckardt A (2005). Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23, 5568-5577.
6. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA. Eastern Cooperative Oncology Group (2005). Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23, 3562-3567.
7. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
8. Denekamp J (1990). Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9, 267-282.
9. Thorpe PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
10. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, and Denny WA (1991). Potential antitumor agents: 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34, 217-222.
11. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, and Ching L-M (1999). Stimulation of tumours to synthesize tumor necrosis factor-a in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59, 633-638.
12. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, and Begent RH (1996). Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56, 3293-3300.
13. Siemann DW, Mercer E, Lepler S, and Rojiani AM (2002). Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99, 1-6.
14. Green C, Griffiths-Johnson D, Dunmore KR, Robson M, Clark S, and Kelland LR (2005). Marked potentiation of the in vivo antitumor activity of docetaxel in a human prostate cancer xenograft by the vascular targeting agent 5,6 dimethyl xanthenone acetic acid, DMXAA. Proc Am Assoc Cancer Res 46, 2990.
15. Kelland LR (2005). Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 1, 1-9.
16. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumor blood vessels. Nat Rev Cancer 5, 423-435.
17. Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, and Rustum YM (2004). Lack of microvessels in well differentiated regions of human head and neck squamous cell carcinoma A253 is associated with fMR imaging detectable hypoxia, limited drug delivery and resistance to irinotecan therapy. Clin Cancer Res 10, 8005-8017.
18. Rangan SR (1972). A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29, 117-121.
19. Fogh J, Fogh JM, and Orfeo T (1977). One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59, 221-226.
20. Cao S, Durrani FA, and Rustum YM (2004). Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10, 2561-2569.
21. Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks LE, Brito AC, and Brasch RC (1987). Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 162, 205-210.
22. Schmiedl U, Ogan MD, Moseley ME, and Brasch RC (1986). Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: and experimental study in rats. Am J Roentgenol 147, 1263-1270.
23. Aicher KP, Dupon JW, White DL, Aukerman SL, Moseley ME, Juster R, Rosenau W, Winkelhake JL, and Brasch RC (1990). Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res 50, 7376-7381.
24. Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT, and Bellnier DA (2005). Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res 11, 4214-4250.
25. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, and Solaiyappan M (2001). Vascular differences detected by MRI for metastatic versus non-metastatic breast and prostate cancer xenografts. Neoplasia 3, 143-153.
26. Bellnier DA, Gollnick SO, Camacho SH, Greco WR, and Cheney RT (2003). Treatment with tumor necrosis factor-α-inducing 5,6-dimethylxanthenone-4- acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 63, 7584-7590.
27. Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69, 89-95.
28. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, and Padhani AR (2002). Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20, 3826-3840.
29. Beauregard DA, Pedley RB, Hill SA, and Brindle KM (2002). Differential sensitivity of two adenocarcinoma xenografts to the antivascular drugs combrestatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15, 99-105.
30. Padhani AR and Leach MO (2005). Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30, 324-341.
31. Baguley BC and Wilson WR (2002). Potential for DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2, 593-603.
32. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. (2002). ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62, 7247-7253.